[Federal Register Volume 87, Number 161 (Monday, August 22, 2022)]
[Notices]
[Pages 51429-51430]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17990]



[[Page 51429]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-22-1279; Docket No. CDC-2022-0093]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing effort to reduce public burden and maximize the 
utility of government information, invites the general public and other 
federal agencies the opportunity to comment on an existing information 
collection, as required by the Paperwork Reduction Act of 1995. This 
notice invites comment on an existing information collection project 
titled WISEWOMAN National Program Evaluation. The goal of the study is 
to assess the implementation of the WISEWOMAN program under the current 
cooperative agreement and measure the effect of the program on 
individual, organizational, and community-level outcomes.

DATES: CDC must receive written comments on or before October 21, 2022.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2022-
0093 by either of the following methods:
     Federal eRulemaking Portal: www.regulations.gov. Follow 
the instructions for submitting comments.
     Mail: Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS H21-8, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. CDC will post, without change, all relevant comments 
to www.regulations.gov.
    Please note: Submit all comments through the Federal eRulemaking 
portal (www.regulations.gov) or by U.S. mail to the address listed 
above.

FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact Jeffrey M. Zirger, Information Collection 
Review Office, Centers for Disease Control and Prevention, 1600 Clifton 
Road, NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118; 
Email: [email protected].

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected;
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses; and
    5. Assess information collection costs.

Proposed Project

    WISEWOMAN National Program Evaluation (OMB Control No. 0920-1279, 
Exp. 12/31/2022)--Extension--National Center for Chronic Disease 
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control 
and Prevention (CDC).

Background and Brief Description

    The CDC has supported the WISEWOMAN (Well-Integrated Screening and 
Evaluation for Women Across the Nation) program since 1995. The 
WISEWOMAN program is designed to serve low-income women ages 40-64 who 
have elevated risk factors for cardiovascular disease (CVD) and have no 
health insurance, or are underinsured for medical and preventive care 
services. Through the WISEWOMAN program, women have access to screening 
services for selected CVD risk factors such as elevated blood 
cholesterol, hypertension, and abnormal blood glucose levels; referrals 
to heathy behavior support programs; and referrals to medical care. 
WISEWOMAN participants must be co-enrolled in the CDC-sponsored 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
    The WISEWOMAN program is administered through cooperative 
agreements with state, territorial, or tribal health departments. Each 
WISEWOMAN recipient submits to CDC an annual progress report that 
describes program objectives and activities, and semi-annual data 
reports (known as minimum data elements, or MDEs) on the screening, 
assessment, and healthy behavior support services offered to women who 
participate in the program. Participant-level MDE are de-identified 
prior to transmission to CDC.
    In 2018, CDC released the fifth funding opportunity announcement 
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal 
health departments, including six new and 18 continuing awardees from 
the previous funding opportunity. Key program elements were retained 
(e.g., provision of screening services, promotion of healthy lifestyle 
behaviors, and linkage to healthy behavior support services and 
community based resources), but a number of changes were incorporated 
into the program at that time. The current FOA reflects increased 
emphasis on three strategies to reduce CVD risk and support 
hypertension control and management, including: (1) tracking and 
monitoring clinical measures; (2) implementing team-based care; and (3) 
linking community resources and clinical services to support care 
coordination, self-management, and lifestyle change.
    CDC seeks to conduct a multi-component evaluation to assess the 
effectiveness of the program on individual, organizational, and 
community-level outcomes. The in-depth assessment is designed to 
complement the routine progress and MDE information already being 
collected from WISEWOMAN program recipients. The data collection 
focuses on obtaining qualitative and quantitative information at the 
organizational and community levels about process and procedures 
implemented, and barriers, facilitators, and other contextual factors 
that affect program implementation and

[[Page 51430]]

participant outcomes. Data collection activities include a Program 
Survey with all WISEWOMAN awardee programs, administered in the second 
and fourth program years, and a one-time site visit to each recipient 
spread across the three-year data collection effort. During site 
visits, semi-structured interviews will be conducted with WISEWOMAN 
staff members and staff at partner organizations, such as clinical 
providers and community-based resource providers, who are positioned to 
provide a variety of perspectives on program implementation.
    OMB approval is requested for a one-year Extension. CDC requests 
approval for an estimated 84 annual burden hours. Participation is 
voluntary and there are no costs to respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
      Type of respondents           Form name        Number of     responses per   per response    Total burden
                                                    respondents     respondent      (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient             Program survey..              16               1               1              16
 Administrators.
                                Site Visit                     8               1           90/60              12
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.
Recipient partners............  Site Visit                    16               1               1              16
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.
Healthy behavior support staff  Site Visit                    16               1               1              16
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.
Clinical providers............  Site Visit                    16               1               1              16
                                 Discussion
                                 Guide.
                                Innovation Site                2               1           45/60               2
                                 Visit
                                 Discussion
                                 Guide.
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............              84
----------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2022-17990 Filed 8-19-22; 8:45 am]
BILLING CODE 4163-18-P